Skip to main content
Log in

Neue Targetstrukturen für antiangiogene Therapien

Grundlagen und Forschungen für die Entwicklung im Rahmen von Oncotyrol

  • Originalarbeit
  • Published:
Wiener klinisches Magazin Aims and scope

Im Rahmen von Oncotyrol, dem Exzel­lenzzentrum für personalisierte Krebsme­dizin in Tirol, wird unter anderem daran geforscht, prädiktive Biomarker zu finden und neue Medikamente und Therapiean­sätze zu entwickeln. Unsere Arbeitsgruppe beschäftigt sich mit der Tumorangioge­nese, also mit der Blutgefäßversorgung von malignen Tumoren. Nachfolgend ge­ben wir einen kurzen Überblick über die Grundlagen und unsere Forschungen zur Tumorangiogenese.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003 Jun;9(6):653-60.

  2. Carmeliet P, Jain RK. Angiogenesis in can­cer and other diseases. Nature 2000 Sep 14;407(6801):249-57.

  3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000 Sep 14;407(6801):242-8.

  4. 4. Keith B, Johnson RS, Simon MC. HIF1al­pha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Can­cer 2012 Jan;12(1):9-22.

    CAS  Google Scholar 

  5. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005 Jun;5(6):423-35.

  6. Jain RK. Normalization of tumor vascula­ture: an emerging concept in antiangiogenic therapy. Science 2005 Jan 7;307(5706):58-62.

  7. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pat­hol 1999 Sep;155(3):739-52.

    Google Scholar 

  8. Yao XH, Ping YF, Bian XW. Contribution of cancer stem cells to tumor vasculogenic mi­micry. Protein Cell 2011 Apr;2(4):266-72.

  9. Carmeliet P, Jain RK. Molecular mecha­nisms and clinical applications of angiogene­sis. Nature 2011 May 19;473(7347):298-307.

  10. Herbert SP, Stainier DY. Molecular cont­rol of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011 Sep;12(9):551-64.

  11. Burri PH, Djonov V. Intussusceptive an­giogenesis–the alternative to capillary sprou­ting. Mol Aspects Med 2002 Dec;23(6S):S1-27.

  12. Adams RH, Alitalo K. Molecular regula­tion of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007 Jun;8(6):464-78.

  13. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cy­tokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neo­vascularization. Nat Med 1999 Apr;5(4):434-8.

  14. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to hu­man tumor vasculature. Nat Med 2005 Mar;11(3):261-2.

  15. Moreno G, V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome re­sistance: rationale and clinical experience. Clin Cancer Res 2012 Jul 15;18(14):3750-61.

  16. Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 2009 Oct;18 Suppl 3:S41-S47.

  17. Bergers G, Hanahan D. Modes of resis­tance to anti-angiogenic therapy. Nat Rev Cancer 2008 Aug;(88):592-603.

  18. Untergasser G, Steurer M, Zimmermann M, Hermann M, Kern J, Amberger A, et al. The Dickkopf-homolog 3 is expressed in tumor en­dothelial cells and supports capillary forma­tion. Int J Cancer 2008 Apr 1;122(7):1539-47.

  19. Fong D, Hermann M, Untergasser G, Pir­kebner D, Draxl A, Heitz M, et al. Dkk-3 ex­pression in the tumor endothelium: a novel prognostic marker of pancreatic adenocarci­nomas. Cancer Sci 2009 Aug;100(8):1414-20.

  20. Muhlmann G, Untergasser G, Zitt M, Zitt M, Maier H, Mikuz G, et al. Immunohistoche­mically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer. Virchows Arch 2010 Jun;456(6):635-46.

  21. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metasta­sis and angiogenesis. Oncogene 2009 Oct 1;28(39):3442-55.

  22. Medinger M, Tzankov A, Kern J, Pircher A, Hermann M, Ott HW, et al. Increased Dkk3 protein expression in platelets and megaka­ryocytes of patients with myeloproliferative neoplasms. Thromb Haemost 2011 Jan;105(1):72-80.

  23. Folkman J. Antiangiogenesis in cancer the­rapy–endostatin and its mechanisms of action. Exp Cell Res 2006 Mar 10;312(5):594-607.

  24. Kerbel RS. Vasohibin: the feedback on a new inhibitor of angiogenesis. Journal of Clini­cal Investigation 2004 Oct;114(7):884-6.

  25. Sato Y. A novel angiogenesis inhibitor va­sohibin. Seikagaku 2006 Aug;78(8):763-7.

  26. Kern J, Steurer M, Gastl G, Gunsilius E, Untergasser G. Vasohibin inhibits angiogenic sprouting in vitro and supports vascular ma­turation processes in vivo. BMC Cancer 2009;9:284.

    Google Scholar 

  27. Hosaka T, Kimura H, Heishi T, Suzuki Y, Miyashita H, Ohta H, et al. Vasohibin-1 ex­pression in endothelium of tumor blood ves­sels regulates angiogenesis. Am J Pathol 2009 Jul;175(1):430-9.

    Google Scholar 

  28. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endo­plasmic reticulum stress. Methods 2005 Apr;35(4):373-81.

  29. Lee AS. GRP78 induction in cancer: the­rapeutic and prognostic implications. Cancer Res 2007 Apr 15;67(8):3496-9.

  30. Li J., Lee AS.: Stress induction of GRP78/ BiP and its role in cancer. Curr Mol Med. 6(1), 45–54 (2006) Feb

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Gerold Untergasser or Eberhard Gunsilius.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kern, J., Untergasser, G. & Gunsilius, E. Neue Targetstrukturen für antiangiogene Therapien. Wien klin Mag 15, 6–9 (2012). https://doi.org/10.1007/s00740-012-0027-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00740-012-0027-x

Navigation